Article

Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells

2020-07-22

Abstract excerpt

Development of targeted therapies for triple-negative breast cancer (TNBC) is an unmet medical need. Cisplatin has demonstrated its promising potential for the treatment of TNBC in clinical trials; however, cisplatin treatment is associated with hypoxia that in turn promotes cancer stem cell (CSC) enrichment and drug resistance. Therapeutic approaches to attenuate this may lead to increased cisplatin efficacy in t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 60406105-7c13-52b6-92e2-3dbeb877f05c
DOI: 10.20944/preprints202007.0527.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem CellsDOI 10.20944/preprints202007.0527.v1Read

Unraveling the triad of hypoxia, cancer cell stemness, and drug resistanceSemantic proximity Read

Cancer stem cells are prevalent in the basal-like 2 and mesenchymal triple-negative breast cancer subtypes in vitroSemantic proximity Read

Enrichment of breast cancer stem cells following cytotoxic chemotherapy is mediated by hypoxia-inducible factorsSemantic proximity Read

Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer.Semantic proximity Read

Counteracting Chemoresistance with Metformin in Breast Cancers: Targeting Cancer Stem CellsSemantic proximity Read

Chemoresistance to additive PARP/PI3K dual inhibition in triple-negative breast cancer cell lines is associated with adaptive stem cell-like prevalenceSemantic proximity Read

Estrogen Receptor β4 Regulates Chemotherapy Resistance and Induces Cancer Stem Cells in Triple Negative Breast CancerSemantic proximity Read

New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic toolsSemantic proximity Read

Hypoxia‐inducible factor‐2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycinSemantic proximity Read

Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC).Semantic proximity Read

Modeling platinum resistance in a stem-like patient-derived ovarian cancer sampleSemantic proximity Read

Transcriptional profiles of different states of cancer stem cells in triple-negative breast cancerSemantic proximity Read